Neuropace Inc. Common Stock (NPCE)

FairStock Score: 39/100 — MIXED

Key Financials

Strengths

• Revenue growth of 23.9% demonstrates strong top-line momentum

Concerns

• High leverage at 4.87x debt-to-equity increases financial risk and interest expense burden
• Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
• Altman Z-Score of -2.2 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Neuropace Inc. Common Stock is a micro-cap healthcare company valued at $581 million. Revenue stands at $100 million, though the company is currently unprofitable. From a quality standpoint, Neuropace shows distressed Altman Z-Score of -2.2 warrants caution and negative ROE indicating losses. On valuation, the stock is 0.1% FCF yield. Growth dynamics show revenue growing at 23.9% and profit growth of 48.0%. Our composite FairStock Score of 39/100 reflects below-average fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.

Bull Case

Neuropace's 24% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Without a clear path to profitability, continued cash burn forces either dilutive equity raises or debt accumulation that destroys shareholder value. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer